Skip to main content
Premium Trial:

Request an Annual Quote

Decode s Q1 Revenues Rise 6 Percent As Losses Swell 20 Percent

NEW YORK, May 2 (GenomeWeb News) - Decode Genetics yesterday reported an approximately 6-percent increase in first-quarter revenues despite escalating losses.


Decode's revenues for the quarter ended March 31 rose to $10.1 million from $9.5 million year over year.


Decode said that R&D expenses for the first quarter swelled to $14.9 million from $8.3 million year over year.


The company's net loss swelled 20 percent to $20.3 million from $16.9 million in the year-ago period. Decode attributed the increase to higher R&D costs related to clinical trials and preclinical development work in the company's lead drug-development programs.


As of March 31, Decode had $140 million in cash and cash investments.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.